• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Alliance for Biosecurity elects new co-chairs

Alliance for Biosecurity elects new co-chairs

July 3, 2013
CenterWatch Staff

The Alliance for Biosecurity, a collaboration among pharmaceutical and biotechnology companies, has elected Anders Hedegaard, president and chief executive officer of vaccine-focused biotechnology Bavarian Nordic, and Elizabeth Posillico, Ph.D., president and chief executive officer of antibody therapeutics developer Elusys Therapeutics, its new co-chairs.

They will represent the Alliance before the U.S. government and other agencies to advance the development of new medical countermeasures to be used against chemical, biological, radiological and nuclear threats. Hedegaard and Posillico will each serve a two-year term, which began in June.

The Alliance for Biosecurity was formed in 2005 to improve the nation's biosecurity through the development of medical countermeasures (MCMs) to address bioterrorism and natural pandemic threats. Activities of the Alliance include educating Congress and other government stakeholders about biosecurity and drug development issues, promoting the success of the Biomedical Advanced Research and Development Authority (BARDA), advancing the science of animal model development, accelerating MCM development and presenting consensus policy proposals.

The Alliance has successfully advocated for preserving the BioShield Special Reserve Fund and BARDA to maintain funding for the development and procurement of MCMs.  In addition, several Alliance recommendations for enhancing the regulatory pathway for MCMs and integrating the FDA into the development process were adopted in recently enacted legislation.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing